EDIT to prior post.
First week of July is deadline for Merck to exercise their option on GRNVAC1. <from my Morgan Stanley Conf notes>
Early Data on GRN163L will be given at JUNE 11-15 conference.
Culled From 8K re: Warrants
<<On February 26, 2007, the Company agreed to issue additional warrants to purchase an aggregate of 1,125,000 shares of Common Stock to the Investors ("D Warrants") in connection with the full exercise of the B Warrants. The number of D Warrants issued to the Investors was determined by multiplying the aggregate number of shares purchased upon exercise of the B Warrants by 60%. The D Warrants will be exercisable from time to time, beginning June 13, 2007 until December 15, 2010, and the exercise price will be equal to 120% of the average closing bid prices of the Company's Common Stock for the five trading day period immediately prior to June 13, 2007, not to exceed $12.14 per share. The D Warrants and the shares of Common Stock underlying the D Warrants are being issued pursuant to the Registration Statement>>
And some earlier info:
Geron expects $40M in gross proceeds from stock sale
By Michael Baron
Last Update: 7:44 AM ET Dec 14, 2006
NEW YORK (MarketWatch) -- Geron Corp. (GERN : Geron Corporation Thursday said it's agreed to sell common stock to institutional investors in a deal expected to yield gross proceeds of $40 million. The Menlo Park, Calif., biopharmaceutical company is selling the stock at $8 per share, compared to Wednesday's closing price at $9.34. The deal includes an overallotment option for the sale of an additional $15 million worth of common stock at the same price per share, as well as longer term warrants, exercisable after 180 days, for the purchase of three million shares at an unspecified premium. Geron plans to use the proceeds to fund clinical trials and for regulatory activities. Specifically, it anticipates initiating a clinical trial for its cancer vaccine in 2007, and said it's "on a path" to a regulatory filing and clinical trial for TAT0002, its telomerase activator drug, for patients with HIV/AIDS. In addition, the company said it expects to file an investigational new drug application for the use of therapeutic cells derived from human embryonic stem cells to treat spinal cord injuries. It will also use the funds to conduct multiple trials of GRN163L, its telomerase inhibitor drug, in 2007. >>
|
